Efficacy and Safety of BT200 (Rondaptivon Pegol) in Patients With Type 2B Von Willebrand Disease

Official title

Efficacy and Safety of BT200 (Rondoraptivon Pegol) in Patients With Type 2B Von Willebrand Disease

Overview

This randomized clinical trial with a cross-over design is being conducted at the Department of Clinical Pharmacology at the Medical University of Vienna, and a total of 4-6 patients with type 2B von Willebrand disease (VWD) will participate. The main purpose of this clinical trial is to investigate the efficacy and safety of BT200, a new drug for thrombocytopenic patients with type 2B von Willebrand disease (VWD). Based on previous studies, we expect that this drug will inhibit the breakdown of von Willebrand factor (VWF) in small doses, leading to an increase in von Willebrand factor (VWF), platelet count, and factor VIII. This should also lead to a reduced tendency to bleed. This study will begin with an observation phase and will then proceed in two periods of approximately 64 days each: Placebo or BT200 will be administered subcutaneously at a dose of 12 mg on the first day of the study. After that, patients will self-administer the drug at a dose of 6 mg (0.4 mL) or placebo once a week for another 4 weeks starting the following week (a total of 4 times over a period of 4 weeks). During this time, they will be asked to come to our clinic for a follow-up visit. After a "washout phase" lasting several weeks, during which patients do not receive the study drug/placebo but are asked to record any bleeding events, the second period begins on day 64: BT200 or placebo is administered again, depending on what the patients received in the first period. Patients therefore receive the study drug for 4 weeks and placebo for 4 weeks; which is administered when is randomized; a follow-up examination also takes place during this period. At the end of the second period, there is another "washout phase" lasting several weeks. On day 127, the final examination takes place at the clinic, after which patients have the opportunity to participate in an extension study (to be amended).

Interventions

• Drug BT200
  Aptamer directed against the A1 domain of von Willebrand factor
• Drug Placebo
  Placebo for BT200

Primary outcome measures

• Primary Outcome measure Platelet Counts [Time frame: During the five-week Treatment Phase compared with the five-week Control Phase]
• Co-Primary Endpoint Clinically evident bleeding [Time frame: During the five-week Treatment Phase compared with the five-week Control Phase]

Secondary outcome measures (10)

• von Willebrand factor antigen [Time frame: During the five-week Treatment Phase compared with the five-week Control Phase]
• von Willebrand factor activity [Time frame: During the five-week Treatment Phase compared with the five-week Control Phase]
• VWF activity collagen binding [Time frame: During the five-week Treatment Phase compared with the five-week Control Phase]
• VWF:ristocetin co-factor activity [Time frame: During the five-week Treatment Phase compared with the five-week Control Phase]
• Enzyme-linked immunosorbent assay (ELISA) for unbound VWF-A1 domain (REAADS® ) [Time frame: During the five-week Treatment Phase compared with the five-week Control Phase]
• Platelet function under high shear rates [Time frame: During the five-week Treatment Phase compared with the five-week Control Phase]
• BT200 plasma concentrations [Time frame: During the five-week Treatment Phase compared with the five-week Control Phase]
• Serious, drug-related AEs [Time frame: During the five-week Treatment Phase compared with the five-week Control Phase]
• Premature terminations due to drug-related AEs [Time frame: During the five-week Treatment Phase compared with the five-week Control Phase]
• Adverse events indicative of BT200 toxicity [Time frame: During the five-week Treatment Phase compared with the five-week Control Phase]

Eligibility criteria

Inclusion criteria

• ≥18 years old
• Type 2B VWD with thrombocytopenia and a recent bleeding history (e.g. recurrent haematomas)
• Able to comprehend and to give informed consent
• Able to cooperate with the Investigator, to comply with the requirements of the study, and to complete the full sequence of protocol-related procedures

Exclusion criteria

• Clinically significant medical history or ongoing chronic illness that would jeopardise the safety of the patient or compromise the quality of the data derived from his/her participation in this study
• History of significant drug allergy or anaphylactic reactions
• Substance abuse, mental illness, or any reason that makes it unlikely in the judgment of the Investigator for the patient to be able to comply fully with study procedures
• Use of medication during 2 weeks before the start of the study, which in the judgment of the Investigator may adversely affect the patient's welfare or the integrity of the study's results
• Concurrent treatment with other experimental drugs or participation in another clinical trial with any investigational drug within 30 days or 5 elimination half-lives (whichever is longer) prior to treatment start

Criteria are shown verbatim from the registry (in English). Final eligibility is always assessed by the study center.

Healthy volunteers: No

Study design

Allocation

Randomized

Model

Crossover

Masking

Quadruple blind

Primary purpose

Treatment

Study locations

Austria · 1 center

• Medical University of Vienna, Department of Clinical Pharmacology — Vienna

Identifiers

NCT: NCT07273721 · BT200-VWD2B Version 1.1 · 2024-518294-34-01

Primary sources (government registries)

• ClinicalTrials.gov (US NIH)

View this study on ClinicalTrials.gov ↗